MDMA and brain activity during neurocognitive performance: An overview of neuroimaging studies with abstinent ‘Ecstasy’ users by Roberts, Carl A et al.
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2018
MDMA and brain activity during neurocognitive performance: An overview
of neuroimaging studies with abstinent ‘Ecstasy’ users
Roberts, Carl A; Quednow, Boris B; Montgomery, Catharine; Parrott, Andrew C
DOI: https://doi.org/10.1016/j.neubiorev.2017.07.015
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: https://doi.org/10.5167/uzh-144008
Journal Article
Published Version
 
 
The following work is licensed under a Creative Commons: Attribution 4.0 International (CC BY 4.0)
License.
Originally published at:
Roberts, Carl A; Quednow, Boris B; Montgomery, Catharine; Parrott, Andrew C (2018). MDMA and
brain activity during neurocognitive performance: An overview of neuroimaging studies with abstinent
‘Ecstasy’ users. Neuroscience and Biobehavioral Reviews, 84:470-482.
DOI: https://doi.org/10.1016/j.neubiorev.2017.07.015
Contents lists available at ScienceDirect
Neuroscience and Biobehavioral Reviews
journal homepage: www.elsevier.com/locate/neubiorev
Review
MDMA and brain activity during neurocognitive performance: An overview
of neuroimaging studies with abstinent ‘Ecstasy’ users
Carl A. Robertsa,⁎, Boris B. Quednowb, Catharine Montgomeryc, Andrew C. Parrottd,e
a Department of Psychological Sciences, University of Liverpool, UK
b Experimental and Clinical Pharmacopsychology, Department of Psychiatry, Psychotherapy, and Psychosomatics, Psychiatric Hospital, University of Zurich, Zurich,
Switzerland
c School of Natural Sciences and Psychology, Liverpool John Moores University, UK
d Department of Psychology, Swansea University, Swansea, UK
e Centre for Human Psychopharmacology, Swinburne University, Melbourne, Australia
A R T I C L E I N F O
Keywords:
MDMA
Ecstasy
Memory
Cognition
fMRI
fNIRS
EEG
ERP
Neuroimaging
Serotonin
Neurotoxicity
A B S T R A C T
MDMA/Ecstasy has had a resurgence in popularity, with recent supplies comprising higher strength MDMA,
potentially leading to increased drug-related harm. Neurocognitive problems have been widely reported in
ecstasy users, equally some studies report null ﬁndings, and it remains unclear which factors underlie the de-
velopment of neurocognitive impairments. This review covers the empirical research into brain activity during
neurocognitive performance, using fMRI, fNIRS, and EEG. Our main conclusion is that chronic repeated use of
recreational ecstasy can result in haemodynamic and electrophysiological changes that reﬂect recruitment of
additional resources to perform cognitive tasks.
Findings are consistent with serotonergic system changes, although whether this reﬂects neurotoxicity or
neuroadaptation, cannot be answered from these data. There is a degree of heterogeneity in the methodologies
and ﬁndings, limiting the strengths of current conclusions. Future research with functional neuroimaging paired
with molecular imaging, genetics or pharmacological challenges of the serotonin system may help to decipher
the link between serotonergic and cognitive changes in ecstasy users.
1. MDMA: general introduction and eﬀects on serotonin
3,4-methylenedioxymethamphetamine or MDMA has recently un-
dergone a resurgence in popularity. According to the European
Monitoring Centre for Drugs and Drug Addiction (EMCDDA) European
drug report 2016, around 2.1 million young adults (15–34) used ec-
stasy/MDMA recreationally in the European Union last year (1.7% of
total population for this age group). In the UK there has been a statis-
tically signiﬁcant increase in prevalence of use in 15–34 year olds from
a low point of 2.5% in 2012, to 3.5% in 2014. This followed a gradual
decline in use since 2000 where prevalence was 4.5% in this population
(European drug report, 2016). This return in popularity follows in-
novations by drug producers to improve negative perceptions about low
quality ecstasy in the drug market. This has led to increases in tablet/
powder/crystal strength, so that many MDMA pills now often contain
around 150 mg of MDMA (Drugs Information and Monitoring System,
Annual Report 2015). Thus recreational ecstasy use poses a serious
public health concern and highlights new challenges that the modern
drug market poses (EMCDDA European Drug Report, 2016). Harm re-
duction strategies are thus urged to target novice users who are con-
suming high strength MDMA without being aware of the related psy-
chological and psychobiological harm.
MDMA is a stimulant and empathogen drug, which can generate
powerful feelings of euphoria and closeness to others, and which is used
recreationally as ‘Ecstasy’ (Degenhardt and Hall, 2009; McCann and
Ricaurte, 2007; Parrott, 2001, 2004, 2013). It has a particular aﬃnity
for the serotonin transporter (SERT), but it also aﬀects other mono-
amine reuptake mechanisms such as the norepinephrine transporter
(Hysek et al., 2011), therefore it has more wide ranging actions than
many ‘classic’ stimulants (McDowell and Kleber, 1994). Nevertheless,
its primary mode of action is to reverse the normal actions of the ser-
otonin transporter, and this can release 80% of available serotonin into
the synapse (Green et al., 1995). Pre-clinical research has established
that repeated dosing with high doses of MDMA causes ‘serotonergic
neurotoxicity’ in rats, monkeys, and other animal species, with reduced
serotonin activity speciﬁcally in cortical brain regions. With humans,
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the ﬁrst neuroimaging studies found a reduced density of serotonin
transporters speciﬁcally in thalamic and striatal regions in abstinent
Ecstasy/MDMA users (McCann et al., 1998; Semple et al., 1999). Lower
indices of serotonin activity have been conﬁrmed in many subsequent
human studies, using an array of neuroimaging procedures
(Benningﬁeld and Cowan, 2013; Cowan 2007; Di Iorio et al., 2012;
Erritzoe et al., 2011; Kish et al., 2010; Reneman et al., 2006).
The working hypothesis for these serotonergic changes is that they
reﬂect distal axotomy – the loss of synaptic terminals from the long-ﬁne
serotonin axons terminating in the higher brain regions. There is an
ongoing debate over whether such serotonergic changes reﬂect neuro-
degeneration, or other changes such as neuroplasticity (Biezonski and
Meyer, 2011). Whatever the underlying mechanism is, serotonin ac-
tivity is clearly reduced after chronic MDMA exposure. After reviewing
the alternative explanatory models, Biezonski and Meyer (2011) con-
cluded: “Given the plethora of evidence showing the 5-HT and SERT-de-
pleting eﬀects of MDMA, this substance can certainly be considered ‘neu-
rotoxic’ in terms of causing serotonergic dysfunction” (p. 86). In another
review which included further empirical ﬁndings, Benningﬁeld and
Cowan (2013), similarly concluded: “The current evidence strongly sug-
gests that human recreational MDMA use leads to chronic reductions in
neocortical serotonin signalling” (p. 255).
In the following sections, imaging studies are reviewed that in-
vestigated the link between brain functions and cognitive performance
in human MDMA users employing molecular imaging (e.g., positron
emission tomography [PET] and single-photon emission computed to-
mography [SPECT]), functional neuroimaging (e.g., functional mag-
netic resonance imaging [fMRI]), electroencephalography (EEG), and
near-infrared spectroscopy (fNIRS). Given the focus of this review on
neurocognition, is important to note that most studies in this area at-
tempt to control for IQ diﬀerences, and in the majority of cases there is
little diﬀerence in IQ between ecstasy using populations and controls
(e.g. Roberts et al., 2013a; Roberts and Montgomery, 2015a,b).
2. Molecular imaging studies with cognitive performance
measures
Reneman et al. (2000) investigated whether MDMA use produced
alterations to post-synaptic 5-HT2A receptors and memory function, by
administering the – radioligand [123I]R91150, as well as a verbal
memory test (Rey Auditory Verbal Learning Test – RAVLT) to 5 MDMA
users and 9 controls. Binding ratios were signiﬁcantly higher in the
MDMA user group, in the occipital cortex. It is suggested that the higher
density of 5-HT2A receptors, reﬂects upregulation of postsynaptic 5-
HT2A receptors as a result of 5-HT depletion. Performance on the
memory task was signiﬁcantly reduced in MDMA users relative to
controls and this was correlated with mean 5-HT2A receptor binding in
the MDMA group. The authors suggest that these results reﬂect memory
deﬁcits that are attributable to MDMA induced 5-HT deﬁcits. However,
it was also conceded that this should be treated as pilot data, due to the
small sample size.
Serotonin transporter densities were examined in 22 current MDMA
users, 13 former users and 13 controls by Reneman et al. (2001). SERT
and memory function (using the RAVLT) were assessed to observe if
there were correlations between the two and whether prolonged ab-
stinence could lead to recovery. Current MDMA users displayed lower
cortical [123I]ßCIT binding than controls, however, no signiﬁcant dif-
ferences in binding were observed between former users and controls.
Immediate and delayed recall performance on the RAVLT was poorer
for both ecstasy user groups relative to controls. However, this was not
correlated with [123I]ßCIT binding. It was concluded that the lower
SERT densities in current MDMA users reﬂects neurotoxic eﬀects, which
may be reversible.
McCann et al. (2008) conducted PET using [11C]DASB to investigate
SERT binding, alongside [11C]WIN 35,428 to investigate dopamine
transporter (DAT) binding. The MDMA users in this study had all
reported having sequential doses of MDMA (2 or more doses over a
3–12 h period). Subjects also underwent formal neuropsychiatric
testing (tests of memory, attention and executive function). The results
indicated that SERT binding was signiﬁcantly reduced in multiple brain
regions for MDMA users relative to controls (occipital cortex, parietal
cortex, temporal cortex, anterior cingulate cortex, posterior cingulate
cortex, dorsolateral prefrontal cortex [DLPFC], and hippocampus). The
reductions were greatest in cortical regions (especially the occipital
cortex) and there were no signiﬁcant diﬀerences in SERT binding in
subcortical regions. No diﬀerences were observed between users and
controls in DAT binding in the caudate or putamen, and no relationship
was found between measures of MDMA use and DAT binding, sug-
gesting normal dopamine function. There was, however, a signiﬁcant
negative correlation between SERT availability in the hippocampus and
duration of MDMA use. These results reﬂect the speciﬁcity of MDMA as
a selective serotonin neurotoxin and suggest that sequential dosing is
associated with lasting decreases in SERT. Memory performance was
also correlated with SERT binding in the DLPFC, orbitofrontal cortex
and parietal cortex, across groups. However, curiously the strength of
this relationship was greater in controls than in MDMA users suggesting
that MDMA use potentially disrupts this relationship, or that compen-
satory recruitment of other resources are being used.
Kish et al. (2010) undertook a comprehensive neuroimaging and
cognitive performance study of 49 moderate Ecstasy users, and 50 non-
user controls. They found signiﬁcant SERT binding reductions in every
region of the cerebral cortex, and the hippocampus. A particular
strength of this study was the wide range of potential confounds being
controlled: recent MDMA use was conﬁrmed through biochemical
analysis of hair samples, the inﬂuence of other psychoactive drugs was
systematically covered, while gender, gene polymorphism, and chronic
tolerance, were also monitored. For these reasons, it was concluded that
SERT binding reductions were not related to structural brain changes,
polydrug use, blood testosterone or estrodial levels, gender, psyvho-
loical health or SERT gene polymorphism. The study included a neu-
rocognitive test battery, and whereas performance on simpler tasks
such as Trail Making Test-A were normal, more complex tasks such as
Trail Making Test-B and California Word Learning were signiﬁcantly
impaired. Furthermore, lower performance on short-term-memory tasks
was correlated with lower SERT within the insular cortex and hippo-
campus.
An imaging study employing 2-deoxy-2-(18F)ﬂuoro-D-glucose
Positron Emission Tomography (in rest) in 19 male MDMA users and 19
male drug-naïve controls revealed that MDMA users show signiﬁcantly
decreased regional cerebral brain glucose metabolism (rMRGlu) in the
bilateral dorsolateral prefrontal and inferior parietal cortex, bilateral
thalamus, right hippocampus, right precuneus, right cerebellum, and
pons (at the level of raphe nuclei) (Bosch et al., 2013). Within the
MDMA user group, worse verbal learning and delayed recall perfor-
mance were correlated with lower rMRGlu in bilateral frontal and
parietal brain regions, while reduced recognition performance was
additionally associated with less rMRGlu in the right mediotemporal
and bihemispheric lateral temporal cortex. Moreover, a higher cumu-
lative lifetime dose of MDMA was related to lower rMRGlu in the left
dorsolateral and bilateral orbital and medial prefrontal cortex, left in-
ferior parietal and right lateral temporal cortex. The authors therefore
concluded that memory deﬁcits related to MDMA use arise from a
combined fronto-parieto-mediotemporal dysfunction.
Thus, there are several molecular imaging studies that report neu-
rocognitive performance changes that are in parallel with serotonergic
and metabolic adaptations following repeated use of MDMA. One
strength of using PET and SPECT imaging is that radioligands can be
used that show speciﬁcity for SERT or 5-HT2A receptors, this can re-
duce the potential for polydrug use to confound results as the most
commonly co-used drugs are not known for their serotonergic eﬀects.
MDMA use is regularly associated with SERT reductions (for a meta-
analysis and review see Roberts et al., 2016b), whereas the association
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between SERT and cognitive performance is less clear. Kish et al. (2010)
use a large sample as well as controlling for many confounders and
suggest SERT reductions are associated with poorer cognitive perfor-
mance. McCann et al. (2008) also note this association but suggest this
is not MDMA speciﬁc. Overall the data are in line with neuroimaging
measures being able to detect neuronal adaptation prior to functional
deﬁcits manifesting themselves.
3. fMRI studies and neurocognitive performance (Table 1)
In the ﬁrst functional imaging experiment with ecstasy users,
Daumann et al. (2003a) administered an n-back task to 11 moderate
ecstasy users, 11 heavy users and 11 healthy controls, during fMRI.
Task performance was equivalent between groups and there were no
diﬀerences in activation at any level of the task at p < 0.05 level
(corrected). Whereas using a more liberal signiﬁcance level (p < 0.01,
and p < 0.001 uncorrected) heavy users showed weaker BOLD re-
sponses in left frontal and temporal regions on the most diﬃcult level of
the task (2-back) relative to the other two groups. Also, both user
groups showed increased activation in the right parietal cortex with 1
and 2 back tasks. However, extent of previous drug use did not correlate
with BOLD signal changes. It is suggested that these results may reﬂect
subtle brain functioning alterations associated with MDMA use. Given
that at the most appropriate corrected signiﬁcance level, ecstasy users
showed cortical activations that are equivalent to controls, and that
there were no performance diﬀerences between groups, as well as small
sample size it seems pertinent to treat this study as an exploratory
analysis for future research to build on.
In a similar fMRI/n-back study, Daumann et al. (2003b) studied
BOLD activation in 8 pure ecstasy users (no regular use of any other
drugs), 8 ecstasy polydrug users, and 8 healthy controls. Performance
on the n-back was equivalent between the three groups and all groups
showed typical cortical activation patterns during the task. At the more
diﬃcult 2-back level of the task, pure MDMA users showed lower ac-
tivation than both other groups in the angular gyrus. It is concluded
from these results that MDMA is associated with neuronal alterations
that may reﬂect MDMA-induced neurotoxicity and that altered fMRI
patterns are not associated with concomitant use of other drugs. The
strength of this study is the inclusion of what the authors term a ‘pure’
ecstasy user group, as an attempt to reduce ﬁndings from polydrug use.
At the most diﬃcult level of the task MDMA users showed reduced
BOLD compared to both other groups in the inferior temporal gyrus, the
angular gyrus and the striate cortex, suggesting an ecstasy-speciﬁc ef-
fect in these brain regions that is more pronounced as task diﬃculty
increases. However, as with many studies in this area the sample size is
potentially problematic when interpreting the eﬀects.
Furthermore, a longitudinal study from the same research group
(Daumann et al., 2004) conducted an 18-month follow-up fMRI study,
using the n-back in ecstasy polydrug users. The ecstasy users were ca-
tegorised according to whether they chose to continue (n = 5) or cease
(n = 8) use during the 18-month period. Task performance was
equivalent between groups at time 1 and 2. fMRI results at time 1
suggested no diﬀerences in cortical activation between the two groups.
At time 2 cortical activation patterns did not alter signiﬁcantly for any
level of the n-back task from baseline in the interim abstention group,
whereas the continuing users showed increased activation from base-
line in two clusters in the parietal cortex during the most diﬃcult level
of the task (2-back). Correlational analysis revealed that in the con-
tinuing users, increase in haemodynamic activation between time 1 and
time 2 in the two clusters in the parietal cortex was associated with
higher one-night dose of MDMA. Consequently, the results suggest a
role for higher nightly doses in neuronal damage. The authors also
suggest that neuronal damage in ecstasy users is long lasting, as the
interim abstinent group did not diﬀer (or improve) in their activation at
time 2 compared to time 1, assuming that activation at time 1 was
atypical. The use of a longitudinal design obviates the problemsT
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associated with between groups designs and can assess eﬀects of con-
tinued use over time. However, the attrition rate has a tendency to
increase over longer periods of time, which explains the small sample
size for follow up analysis despite recruiting 30 participants into the
study initially. Nevertheless, this study provides some interesting evi-
dence that continued use can lead to further neuronal changes (despite
equivalent task performance between time 1 and time 2). Unfortunately
these results are complicated somewhat by continuing users, also using
amphetamines, whereas the abstinent group had abstained from am-
phetamine use also.
Moeller et al. (2004) studied activation in 15 MDMA users and 19
controls, whilst completing an immediate and delayed memory task.
Ecstasy users displayed signiﬁcantly greater BOLD activation in the left
medial and superior frontal gyri, the left thalamus and right hippo-
campal gyrus. Most of these eﬀects remained after controlling for use of
other drugs. However, after controlling for cannabis, the eﬀect was no
longer signiﬁcant in the prefrontal cortex. The authors suggest that the
observed increase in activation of the BOLD signal could be due to
MDMA users being less “eﬃcient” at the working memory task, re-
sulting in an increase in neuronal activity to perform at a similar level
as controls. They also argue that increased BOLD fMRI activation in the
hippocampus may be MDMA speciﬁc. Similarly Jacobsen et al. (2004)
observed a reduction in left hippocampal deactivation (i.e. greater ac-
tivation) in a group of 6 adolescent MDMA users relative 6 controls
(matched for age and gender) at the most diﬃcult level of an n-back
working memory task, despite equivalent task performance. Correla-
tional analysis revealed that time since last use was negatively corre-
lated with left hippocampal activity, whereby more recent users had
greater activation as measured by percent signal change, than those
with the greatest duration of abstinence, potentially reﬂecting recovery
of hippocampal neuro-circuitry after long periods of abstinence. How-
ever this study is described as a pilot study due to its small sample and
lack of pre-MDMA exposure data. Conversely, hippocampal activity was
restricted in ecstasy users relative to controls (analysis was conﬁned to
the hippocampus) whilst performing at an equivalent level in an epi-
sodic memory retrieval task (Daumann et al., 2005), again the authors
concluded that fMRI results provide an index of abnormal cognitive
function in the absence of memory deﬁcits. A more recent prospective
study (Becker et al., 2013) assessed hippocampal function during an
associative memory task in 40 ecstasy users who had minimal exposure
to ecstasy ( < 5 tablets, as well as <5 g of amphetamine) at time 1, and
17 participants who had continued ecstasy but had limited ampheta-
mine use 12 months later at time 2 (interim dose of 9.5 tablets). There
were no signiﬁcant diﬀerences on task performance between Times 1
and 2. However, encoding related activity in the left parahippocampal
gyrus decreased in the continuing ecstasy/amphetamine user group at
time 2. This decrease in activation inversely correlated signiﬁcantly
with interim ecstasy use, but not amphetamine use, leading the authors
to conclude that moderate use of ecstasy is related to changes in hip-
pocampal functioning.
Jager et al. (2008) assessed the concomitant use of other drugs in 71
participants recruited on the basis of variations in the amount and type
of drugs that they used. Thirty-three heavy MDMA users (322 tablets)
and 38 non users (both groups showing considerable variation in the
type and amounts of drugs they were using) completed tasks of working
memory, attention and associative memory tasks in association with
fMRI procedures. This study employed multiple regression analyses to
parse drug eﬀects on cognitive performance. Ecstasy use indices did not
predict cognitive performance in any of the 3 domains being in-
vestigated. Moreover, there were no signiﬁcant eﬀects of ecstasy or any
other drugs on brain activity relating to working memory (modiﬁed
Sternberg task) and attention (Selective Attention Task). However, in
the associative learning task ecstasy use predicted lower activity in the
left DLPFC and higher activation in the right middle occipital gyrus.
The authors suggest these results reﬂect long term adaptation or com-
pensatory reorganisation of a fronto-visual network. Conversely the
same research group (Jager et al., 2007) observed no behavioural or
neurophysiological eﬀects of a ‘low dose’ of ecstasy during working
memory, associative memory and attention tasks, in a prospective study
on 25 participants pre and post their ﬁrst ecstasy using episode. Taken
together, these results suggest that a single episode of a low dose of
ecstasy (such as those given in MDMA assisted psychotherapy) may
have limited neuroadaptation impact compared to higher doses (such as
that associated with recreational ecstasy use).
BOLD signal change during a semantic recognition task (in which,
performance was not associated with MDMA use) in 12 ecstasy poly-
drug users was assessed by Raj et al. (2010) in a region of interest fMRI
analysis (left BA 9, 18, 21/22 and 45). Lifetime episodes of MDMA use
and lifetime dose were both inversely correlated with%BOLD signal
change at BA 9. Lifetime episodes of use was inversely correlated with
BOLD signal change in BA 18 and 21/22, though no such correlations
were observed for the encoding phase of the task, suggesting that
MDMA aﬀects verbal recognition but not encoding. These results were
complicated by inverse correlations between lifetime cocaine use and
BOLD signal activation in left BA 9 and 18 as well as a statistically
signiﬁcant inverse correlation between cannabis use and activation in
left BA 9. Nonetheless, after controlling for lifetime cocaine and can-
nabis use, the association between MDMA use and BA 9 activation re-
mained statistically signiﬁcant. Correlational analyses such as these can
give us an indication of cumulative eﬀects of ecstasy on neural acti-
vation; however using lifetime episodes as an indicator of intensity of
use is problematic as this does not give an indication of nightly doses.
Furthermore this study had a small sample size and all participants
were polydrug users (with a fairly high amount of LSD and metham-
phetamine use).
Semantic memory was also investigated by Watkins et al. (2013)
with a two-part fMRI encoding and recognition task. Twenty-three ec-
stasy users were compared to 11 controls, and whilst their task per-
formance did not diﬀer, activation was greater during the encoding
phase of the task for ecstasy users in BA7, 39 and 40. Furthermore peak
activation in the right superior parietal lobe was correlated with life-
time dose of ecstasy. Once again this study demonstrates an ecstasy-
related decrease in cortical eﬃciency for semantic memory.
Neurophysiological correlates of impulse inhibition were explored
in 20 ecstasy users and 20 drug naïve controls by Roberts et al., 2009.
fMRI data showed that ecstasy users displayed greater activity in right
middle and inferior frontal gyri, right middle frontal gyrus and right
inferior parietal lobule, during successful response inhibitions (STOPS)
on a Go/NoGo task, compared to controls. Ecstasy users also displayed
greater error activation in the right middle and inferior temporal gyri.
Deactivation in the left medial frontal gyrus and left posterior cingulate
was signiﬁcantly greater for controls on error trials. It is suggested that
the increased activation displayed by ecstasy users despite no sig-
niﬁcant behavioural diﬀerences, shows increased neuronal recruitment
required to inhibit in this group. Recruitment of additional resources to
maintain performance, suggests a subtle functional impairment that
would have not been exposed with behavioural measures alone. Roberts
et al., 2009 recorded fMRI during another cognitive measure − facial
recognition/learning. The abstinent Ecstasy/MDMA user group were
signiﬁcantly worse at face learning than the illicit drug control group of
abstinent cannabis users, and the legal drug control group of non-users.
The functional neuroimaging revealed hyperactivity in various brain
regions, including the frontal cortex, left temporal lobe, and right
parietal lobe. It also revealed hypoactivity in the anterior cingulate, and
parietal cingulate cortex.
Overall these data suggest that fMRI can be used as a sensitive
measure of neuronal changes prior to the appearance of performance
indicators of cognitive deﬁcits. However, gaining concrete conclusions
from the literature is problematic due to several of these studies having
small sample sizes − a problem that is common in fMRI research.
Moreover to make sense of whether an increase or a decrease in BOLD
reﬂects a subtle neuronal deﬁcit, it is necessary to understand the
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direction of task performance, for example, the strongest indication of
MDMA related neuroadaptation comes from studies such as Moeller
et al. (2004), Watkins et al. (2013), Roberts et al., 2009; Roberts and
Garavan (2010) that suggest signiﬁcant increases in BOLD, despite
equivalent performance, in studies with adequate sample sizes. Pro-
spective studies are a useful tool in this area and can provide in-
formation about neuroadaptation in relation to initiating/continuing
use. Becker et al. (2013) suggest reliable changes in hippocampal
functioning following intake of under 10 tablets. However the hippo-
campal activity in this study is in a diﬀerent direction to that in Moeller
et al. (2004), perhaps reﬂecting divergent hippocampal activity based
on task type (immediate and delayed recall vs associative memory).
4. fNIRS studies and neurocognitive performance (Table 2)
A novel functional imaging technique to assess neurocognition in
ecstasy user populations is functional NIRS. Similar to fMRI, it is an
indirect measure of neuronal activation, based on the principle that
neuronal ﬁring and haemodynamic response are closely linked. This
technique uses near-infrared light to calculate amounts of circulating
oxy and deoxy-Hb in the PFC. There are currently only 3 published
articles in the ecstasy-neurocognition literature, the ﬁrst of which
(Roberts et al., 2014) assesses performance of ecstasy polydrug users,
polydrug controls and drug naïve controls during a multitasking
stressor. Multitasking performance was similar between groups in this
instance; however, fNIRS suggested ecstasy users displayed lower
oxygenated Hb response relative to drug naïve controls in the left
DLPFC and the right DLPFC, which the authors conclude could be re-
lated to cerebral vasoconstriction. Roberts and Montgomery (2015a)
observed increases in oxy-hb in ecstasy users relative to controls during
equal performance on an inhibitory control task in several voxels in-
dicating increased activation in the inferior right medial prefrontal
cortex, and the right and left dorsolateral prefrontal cortex. Interest-
ingly, a regression analysis suggested that after controlling for alcohol
and cannabis use indices, recency of ecstasy use was a signiﬁcant pre-
dictor of oxy-Hb at 2 voxels pertaining to the right PFC. Similarly,
during a word ﬂuency task completed by 20 ecstasy users and 20 non-
user controls (Roberts and Montgomery, 2015b), ecstasy users dis-
played increased oxy-Hb compared to controls over several voxels lo-
cated over the left DLPFC and the right medial PFC. Performance was
equivalent between groups. Further to this, ecstasy use indices − life-
time dose, last 30-day use and frequency of use were signiﬁcant pre-
dictors of oxy-Hb increase in several voxels, after controlling for alcohol
and cannabis indices. The interpretation of these two studies is that
ecstasy users are showing heightened responses (increased eﬀort) in 5-
HT rich areas of the PFC to achieve similar performance to controls
during executive tasks. This is understood to be a compensatory me-
chanism necessitated by neurocognitive decline (Table 2).
5. Electroencephalograpy and sensory evoked potential stuides
In two highly similar studies, Tuchtenhagen et al. (2011) and Croft
et al. (2001) investigated the intensity dependence of auditory evoked
potentials with EEG, which has been suggested as an electro-
physiological index of serotonergic functioning (Hegerl and Juckel
1993; Juckel et al., 1997). In both studies, currently abstinent, long-
term MDMA users showed a signiﬁcantly stronger gradient of their EEG
response to increasing loudness of auditory stimuli compared to regular
cannabis users as well as drug-naive controls. Only in the study of Croft
et al. (2001), the degree of electrophysiological stimulus intensity de-
pendence was positively correlated with cumulative lifetime use of
Ecstasy tablets. The authors from both studies concluded that the
electrophysiological pattern was theoretically consistent with the no-
tion of an MDMA-induced serotonergic impairment. In a subsequent
longitudinal study, Daumann et al. (2006) assessed the loudness de-
pendence of auditory evoked potentials (LDAEP) at baseline and at an
18-months follow-up in an independent sample of 18 MDMA users
without ascertaining a control group. Because of problems with the
group assignment and due to a lack of power, abstinent/occasional
users did not diﬀer from continuing users regarding baseline LDAEP or
its change during the interval. However, frequency of MDMA use, cu-
mulative lifetime dose and period of abstinence were associated with
the LDAEP in these users conﬁrming the previous correlation reported
by Croft et al. (2001). Although the LDAEP seem to be stable over time
this result was interpreted again as consistent with a serotonergic
change/neurotoxicity of MDMA. In a subsequent study, Wan et al.
(2009) compared the LDAEP of 16 polydrug users with and 23 polydrug
users without MDMA use. Again MDMA-experienced polydrug users
showed a stronger tangential dipole source activity with increasing
loudness of the acoustic stimuli compared to non-MDMA drug users.
However, the authors reported an unusually high response to the lowest
60 dB stimulus intensity in both groups, so that they excluded this
condition from their ﬁnal analyses. Interestingly, MDMA users showed
a history of more aggressive behaviour and higher aggression scores
were correlated with pronounced intensity stimulus dependence of the
source activity. Moreover, in a classiﬁcation analyses intensity depen-
dence as well as aggression scores correctly identiﬁed 73.3% of those
who have used MDMA regularly and 78.3% of those who had not.
Consequently, also these authors concluded that “chronic ecstasy ex-
posure results in serotonin deﬁciency condition” (Wan et al., 2009, p.
1489). Up to now it is, however, still controversial if the intensity de-
pendence of auditory evoked potentials in fact reﬂects central serotonin
activity (for discussion please see: Juckel, 2015; O'Neill et al., 2008).
Casco et al. (2005) investigated amplitude and latency of visual
evoked potentials (VEP) employing EEG in small groups of 8 heavy
MDMA users (mean 1054 exposures lifetime), 8 moderate MDMA users
(52 exposures lifetime), and 18 drug-free control participants. With the
exception of one individual, all users reported to be abstinent for at
least 6 months. In a simple psychophysical discrimination task the
heavy users committed more errors than both other groups. In com-
parison with the controls, heavy users showed strongly decreased am-
plitudes of the intermediate (P200) and late (P300) components at the
Oz electrode and of the P250 and P300 components at the Fz electrode
in response to the visual stimulation. However, also moderate users
showed signiﬁcantly lower amplitudes of the P300 component at both
investigated electrodes (Oz, Fz) compared to controls. In contrast, the
three groups did not diﬀer in their amplitude of early components
(P100 and N150), reﬂecting intact early processing of visual input. The
authors concluded, “that cortical activity associated with low levels of
cognitive processing is altered after prolonged exposure to ecstasy” (Casco
et al., 2005, p. 193).
6. Electroencephalography and event-related potential studies
(Table 3)
Gamma et al. (2005) employed EEG during a continuous perfor-
mance task and assessed event-related potentials (ERPs) to Go and
NoGo trials in 16 current polydrug MDMA users and 17 MDMA-naïve
controls. Both groups did not diﬀer in task performance and showed
robust and normal patterns of P300 anteriorization and delay in the
inhibition (NoGo) compared to the execution (Go) condition. However,
MDMA users displayed diminished amplitudes of the P300 component
above central midline structures across both conditions, higher P300
NoGo amplitudes over the right posterior cortex, and a less anterior
location of P300 peaks in the NoGo condition. The authors discussed
that lowered midline P300 amplitudes during NoGo trials might reﬂect
reduced cortical inhibition, which would be in line with the observation
of behavioural disinhibition of MDMA users (Morgan, 1998; Quednow
et al., 2007). However, given that the neuroelectric pattern associated
with the switch between execution and inhibition was intact, and that a
less pronounced anteriorization of the P300 wave during NoGo trials is
usually related to less impulsivity, the authors concluded that their
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results do not support disturbed inhibitory brain mechanisms in MDMA
users (Gamma et al., 2005). Of note, some of the healthy controls in this
study reported cannabis, cocaine, LSD, or “magic mushroom” use so
that this non-ﬁnding has to be interpreted with caution.
Meijas et al. (2005) found a complex pattern of behavioural and ERP
diﬀerences between 14 MDMA users and 14 matched normal controls
using a ‘visual oddball’ EEG task in which the participants had to detect
rare faces with fearful expressions among common happy faces. The
authors reported that MDMA users showed slower responses to rare
(fearful) stimuli than the controls. Moreover, MDMA users show gen-
erally decreased N170 amplitudes during face presentation in general.
While controls showed the expected lowered latency of the N200
component to rare fearful stimuli in contrast to common happy stimuli
(reﬂecting attention orientation to novel stimuli) this eﬀect was absent
in MDMA users. Finally, MDMA users showed delayed P3b latencies for
the detection of rare stimuli. The authors debated their ﬁndings in re-
lation to possible changes in attentional processing, particularly to
emotional stimuli, in MDMA users, which again would be theoretically
consistent with a general serotonergic impairment.
De Sola et al. (2008) compared 14 abstinent ecstasy users, 13 can-
nabis users, and 22 non-using controls regarding neurocognitive per-
formance and P300 ERPs at baseline and a one-year follow-up. ERPs
were evoked using an auditory oddball paradigm involving sustained
attention, in which a frequent standard tone and an infrequent “target”
tone has to be detected. At the follow-up but not at baseline, abstinent
MDMA users were signiﬁcantly impaired in neurocognitive tests of se-
mantic word ﬂuency, processing speed, and verbal memory recogni-
tion. Higher lifetime MDMA use was signiﬁcantly associated with
poorer recognition of verbal memory. However, no group diﬀerences in
P300 latency and amplitude were found. P300 latency was correlated
with cannabis but not with MDMA use. The authors concluded that
long-term MDMA use is associated with mild cognitive deﬁcits but not
with changes of the attention-related P300 wave. Because the here in-
vestigated MDMA users did also not show changes in attentional per-
formance (which is in line with recent meta-analyses: Kalechstein et al.,
2007; Rogers et al., 2009), this ﬁnding is consistent with the assump-
tion that memory and executive functions rather than attention pro-
cesses might be aﬀected by chronic MDMA use.
Burgess et al. (2011) studied recognition memory for verbal and
non-verbal content using ERPs in 15 MDMA polydrug users, 14 can-
nabis users, and 13 illicit-drug-naïve healthy controls. In this small
sample, the authors did not ﬁnd signiﬁcant diﬀerences between the
three groups regarding word and face recognition performance. How-
ever, MDMA polydrug users showed lower ERP amplitudes during word
recognition (but not during face recognition) compared to cannabis
users and drug-naive controls. This attenuation of the ERP was re-
stricted to the late positive component over left parietal scalp sites,
which has been linked with memory recollection processes previously,
while the familiarity-related component was unaﬀected. Because of the
speciﬁcity of their results the authors resumed that the disturbances in
word recollection “are consistent with the known serotonergic neurotoxicity
of MDMA” but that “it would be premature to attribute this eﬀect to Ecstasy
use alone” (Burgess et al., 2011, p. 555).
In a further memory ERP investigation, Nulsen et al. (2011) applied
forward and backward serial recognition tasks to 11 MDMA users, 13
polydrug users, and 13 non-drug users in order to engage verbal
working memory during EEG. The three small groups did not diﬀer in
their verbal working memory performance. In controls and polydrug
users, the P3b component over the parietal scalp electrodes (Pz) was
signiﬁcantly larger in the digits forward task than in the digits back-
ward task. In contrast, MDMA users did not display the increased P3b
component in the forward compared to the backward condition. Al-
though MDMA users performed equally well as the other groups, the
authors concluded from their ERP ﬁndings, that putative working
memory deﬁcits of MDMA users might be explained by ineﬀective al-
location of cognitive resources.
In a series of three experiments, Roberts et al. (2013a, b, c), in-
vestigated a sample of 20 MDMA polydrug users, 20 non-MDMA
polydrug users, and 20 drug naïve controls employing a semantic re-
trieval task, a Go/NoGo response inhibition task, and a mental set
switching task in the course of EEG recording. The groups did not
signiﬁcantly diﬀer in their performance in any of these tasks. However,
higher MDMA use intensity predicted a worse performance in the set
switching tasks (switching costs) when recent cannabis use was con-
sidered in the regression model (Roberts et al., 2013c). During the re-
sponse inhibition task, MDMA polydrug users showed a signiﬁcantly
higher mean amplitude of the P200 component at the frontal midline
electrodes Fz and FCz when compared to both polydrug controls and
drug-naïve controls, respectively (Roberts et al., 2013a). In the se-
mantic retrieval task there was a trend for an overall group eﬀect on the
N2 component and further exploration revealed a signiﬁcant diﬀerence
between the MDMA-polydrug users and the drug-naïve controls, which
was explained by a larger negativity of the N2 wave at occipito-parietal
electrodes in the MDMA-experienced polydrug group (Roberts et al.,
2013b). Finally, while performing the mental set switching task (the
number-letter task) both drug groups displayed a reduction in positivity
of the P300 component at parieto-occipital electrodes in comparison to
the drug-naïve controls (Roberts et al., 2013c). Additionally, in MDMA
polydrug users a signiﬁcant increase in negativity of the N2 at several
occipito-parietal electrodes was detected in comparison to non-MDMA
polydrug users and non-drug using controls. The authors concluded
from all three experiments that MDMA users have deﬁcits in the pro-
cessing of executive functions (including response inhibition, set
switching, and semantic memory access) although no performance
deﬁcits have been revealed. This dissociation was explained by “com-
pensatory mechanisms or re-allocation of cognitive resources that are de-
ployed to attenuate any observable behavioural diﬀerences caused by ec-
stasy-related disturbances” (Roberts et al., 2013b, p. 387).
In summary of the ERP data, most researchers suggest that ecstasy
related atypicalties reﬂect serotonergic changes. However, as seen with
the fMRI research, in EEG research there are many experimental pro-
blems which limit consistent interpretation of the data. These again
include small sample sizes, heterogeneous drug user groups and het-
erogeneity of activity (for example increased or decreased P300) that is
open to author interpretation.
7. Conclusions
The evidence from molecular imaging studies is consistent in de-
monstrating alterations of the serotonin system following ecstasy use
(see Roberts et al., 2016b for meta-analysis). Moreover, neurocognitive
performance deﬁcits (immediate and delayed recall, working memory)
are often associated with reduced SERT binding in frontal, parietal and
temporal regions (Kish et al., 2010; McCann et al., 2008). Such areas of
the neocortex have long axon projections from the raphe nuclei and are
understood to be more vulnerable to MDMA neuroadaptation in pre-
clinical studies (Molliver et al., 1990). Similarly, functional imaging
studies assessing haemodynamic responses to neurocognitive tasks
show parallel ecstasy related changes in activity to frontal and temporal
areas perhaps reﬂecting similar neuroadaptation or other putative
changes to the serotonergic system.
fNIRS studies, for example consistently note increases in oxy-Hb in
areas of the PFC associated with executive performance that reﬂects
increased cognitive eﬀort to maintain performance levels. These studies
highlight the importance of measuring the haemodynamic response in
tasks where performance is similar between groups, it also highlights
the dissociation between mental eﬀort and task performance. Ayaz
et al. (2012) noted that in human operators, performance can be
maintained by adopting alternative strategies or increasing mental ef-
fort, however increases in oxy-Hb predict future cognitive failure with
increased demands or task changes. Similar increased activity and re-
cruitment of additional resources is suggested in fMRI experiments that
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observe ecstasy related increases in BOLD activity in prefrontal areas
during cognitive inhibition (Roberts and Garavan, 2010), face re-
cognition Roberts et al., 2009 and immediate and delayed recall
(Moeller et al., 2004). Elevated hippocampal activity is also associated
with ecstasy use, despite equivalent performance during working
memory performance (Jacobsen, 2004; Moeller et al., 2004). Con-
versely MDMA related reductions in hippocampal activity have been
observed during episodic memory (Daumann et al., 2005) and asso-
ciative memory (Becker et al., 2013). Thus the relationship between
MDMA exposure and hippocampal function is not clear from neuro-
cognitive fMRI studies.
Reduced BOLD activation in frontal regions, despite equivalent
performance on updating tasks has been reported (e.g. Daumann et al.,
2003a,b; Jager et al., 2008), however these changes are subtle and in
Daumann et al. (2003a) are reportedly not correlated with ecstasy use.
Moreover, the same group Daumann et al. (2004) suggest increases in
haemodynamic responses in the parietal cortex are associated with
higher nightly doses. Whilst generally the reports on haemodynamic
activity during neurocognition in ecstasy users are interpreted in terms
of increased cognitive eﬀort, or reduced serotonergic signalling, the
direction of the BOLD response (increased or decreased) does suggest a
reasonable amount of inconsistency in the results. One potential reason
for this could be due to diﬀerences in drug use between samples. In-
deed, Jager et al. (2007) suggest that low doses of ecstasy produce little
performance or haemodynamic changes, and thus may not be as det-
rimental as regular heavy use. Interestingly a recent review of fMRI
studies with moderate/light MDMA users suggests that the evidence for
structural and functional brain alterations with low MDMA use is lim-
ited (Mueller et al., 2016). In line with this, the extent of previous drug
use has been reported to be associated with extend of SERT availability
(Kish et al., 2010) and neurocognitive function (Fox et al., 2001). Taken
together, perhaps lifetime dosage is one possible explanatory factor for
some of the inconsistency of the results, with low doses reﬂecting
markedly less pronounced eﬀects.
The ERP data with ecstasy polydrug users, is often interpreted in
terms of atypical/aberrant processing that reﬂects changes to the ser-
otonin system. Many studies report MDMA related alterations of neu-
ronal activation, despite equivalent task performance. This suggests a
greater sensitivity of neuroimaging techniques to detect perhaps subtle
cognitive changes. However, again there are several inconsistencies
with the methodology and results that make drawing ﬁrm conclusions
diﬃcult. For example, the investigated samples across all imaging types
were generally small and investigated heterogeneous groups of poly-
drug users with and sometimes without MDMA use. Several ERP studies
have investigated changes of the P300 wave showing sometimes higher,
lower, or normal amplitudes of this late component (or subcomponents
such as the P3b), or increased/decreased haemodynamic responses
during cognitive processes, which is a good example for the hetero-
geneity of the previous results. While most of the authors interpret their
ﬁnding in the context of the serotonergic neurotoxicity of MDMA, none
of the studies have employed reliable biological markers of the central
serotonin system so far. Moreover, previous studies investigated cog-
nitive functions, such as attention, working memory, and executive
functions, which have been shown to have small to moderate eﬀect
sizes in MDMA users (Kalechstein et al., 2007), while verbal memory
(speciﬁcally delayed recall of words), the domain in which MDMA users
are most impaired, has rarely been investigated in functional imaging
studies − perhaps due to artefact problems which occur from vocali-
sations (with the exception of fNIRS).
It is perhaps not surprising that there are inconsistencies in the
neuroimaging data, if using these techniques is not utilizing function
speciﬁc tasks that more reliably yield performance deﬁcits in ecstasy
users. For example, much of the literature on executive function in
ecstasy users relative to controls has shown to be very inconsistent due
to many executive tasks, or working memory tasks relying on multiple
cognitive abilities. It has been suggested previously (Montgomery et al.,
2005) that, in terms of executive function, there may be a diﬀerential
pattern of performance deﬁcits based on function type and drug use.
Thus working memory tasks, often refer to information processing,
which is understood to be relatively unaﬀected by ecstasy use. In a
meta-analysis by Roberts et al. (2016a) it was observed that using
function speciﬁc tasks, ecstasy users showed performance deﬁcits re-
lative to controls in updating, switching and access to long term
memory. Perhaps using function speciﬁc tasks would improve the
consistency in the literature.
In the future, well-powered studies with more homogeneous drug-
using groups might focus on cognitive functions that have been shown
to be robustly impaired in MDMA users, such as declarative memory,
prospective memory, in order to ﬁnd the neuronal correlates of these
deﬁcits using the neuroimaging techniques. Ideally, these investigations
are paired with molecular imaging, genetics or pharmacological chal-
lenges of the serotonin system in order to decipher the link between
serotonergic and cognitive changes in MDMA users. However, whilst
studies investigating brain activity during cognitive performance in
ecstasy polydrug users require a degree of caution when interpreting
results, many reﬂect altered neuronal functioning that is in line with
neuroadaptation following repeated use. Given the recent increase in
MDMA tablet/powder/crystal strength, then the magnitude of potential
harm is of greater concern. Harm reduction strategies are thus urged to
highlight such concerns to prospective and novice MDMA users.
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